Inhibrx Biosciences, Inc.
Financials
Valuation Metrics
Inhibrx Biosciences, Inc.'s Market Cap is $1.60B. At end of 2025 it was $1.22B. Ranked #2203 of 3,121 in US market (top 71%), #869 of 1,463 on NASDAQ (top 59%), #162 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.60B | US#2,203/3,121 Sec#162/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-138M | US—/3,121 Sec—/266 |
| Total Assets | $154M | US#3,028/3,121 Sec#255/266 |
| Net Assets | $-53M | US#2,955/3,121 Sec#249/266 |
| Employees | 110 | US#2,608/3,121 Sec#171/266 |
| Value | ||
| P/S | 1234.07x | US#2,990/3,121 Sec#199/266 |
| FCF Yield | -8.22% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -89.60% | US#3,053/3,121 Sec#251/266 |
| Revenue Growth | -100.00% | US#2,775/3,121 Sec#187/266 |
| Financial Health | ||
| Total Debt | $5M | US#2,902/3,121 Sec#215/266 |
| FCF | $-132M | US#2,692/3,121 Sec#165/266 |
| Cash | $133M | US#2,030/3,121 Sec#147/266 |
| Current Ratio | 5.07x | US#462/3,121 Sec#143/266 |
| Performance | ||
| 1Y Return | 310.32% | US#30/3,121 Sec#15/266 |
| 1M Return | 7.76% | US#223/3,121 Sec#26/266 |
| From 52W High | -29.58% | US#2,187/3,121 Sec#172/266 |
| 1Y MDD | -44.13% | US#2,215/3,121 Sec#160/266 |
| Trading | ||
| Volume | 422,952 shares | US#2,599/3,121 Sec#249/266 |
| Trading Value | $46M | US#1,793/3,121 Sec#140/266 |
| Per Share | ||
| EPS | $-9.42 | US—/3,121 Sec—/266 |
| BPS | $-3.61 | US—/3,121 Sec—/266 |
Company Info
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.